Article Text

Download PDFPDF
On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis
  1. Theresa Kissel1,
  2. Karin Anna van Schie1,
  3. Lise Hafkenscheid1,
  4. Anders Lundquist2,
  5. Heidi Kokkonen3,
  6. Manfred Wuhrer4,
  7. Tom WJ Huizinga1,
  8. Hans Ulrich Scherer1,
  9. René Toes1,
  10. Solbritt Rantapää-Dahlqvist3
  1. 1Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2Department of Statistics, Umeå University, Umeå, Sweden
  3. 3Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
  4. 4Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Theresa Kissel, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; T.kissel{at}lumc.nl

Footnotes

  • Handling editor Prof Josef S Smolen

  • Correction notice This article has been corrected since it published Online First. An error has been corrected in the abstract.

  • Contributors TK: study concept and design, conducting experiments, aquisition of data, analysis and interpretation of the results, drafting and revising the manuscript, final approval of the manuscript. KAvS: study concept and design, conducting experiments, aquisition of data and interpretation of the results, critical revision and final approval of the manuscript. LH: study concept and design, methodology design, conducting experiments, aquisition of data, critical revision and final approval of the manuscript. AL: statistical analyses, interpretation of the results, critical revision and final approval of the manuscript. HK: statistical analyses, critical revision and final approval of the manuscript. MW: methodology design, critical revision and final approval of the manuscript. TWJH: interpretation of the results, critical revision and final approval of the manuscript. HUS: study concept and design, interpretation of the results, critical revision and final approval of the manuscript. RT: study concept and design, interpretation of the results, drafting and revising the manuscript critically, final approval of the manuscript. SR-D: study concept and design, statistical analyses, interpretation of the results, drafting and revising the manuscript critically, final approval of the manuscript. Department of Biobank Research at Umeå University: providing patient samples and data. Västerbotten Intervention Programme: providing patient samples and data. The Northern Sweden MONICA study: providing patient samples and data. The County Council of Västerbotten: providing patient samples and data. J.W. Drijfhout: providing the CCP2 peptides.

  • Funding This work has been financially supported by ReumaNederland (17-1-402), the IMI funded project RTCure (777357), ZonMw TOP (91214031), the Swedish Research Council (VR 2017-00650) as well as the King Gustaf V’s 80-Year Fund, the King Gustaf V’s and Queen Victoria’s Fund and the Swedish Rheumatism Association.

  • Competing interests HUS, TWJH and REMT are mentioned inventors on a patent on ACPA-IgG V-domain glycosylation.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Prof Josef S Smolen

  • Correction notice This article has been corrected since it published Online First. An error has been corrected in the abstract.

  • Contributors TK: study concept and design, conducting experiments, aquisition of data, analysis and interpretation of the results, drafting and revising the manuscript, final approval of the manuscript. KAvS: study concept and design, conducting experiments, aquisition of data and interpretation of the results, critical revision and final approval of the manuscript. LH: study concept and design, methodology design, conducting experiments, aquisition of data, critical revision and final approval of the manuscript. AL: statistical analyses, interpretation of the results, critical revision and final approval of the manuscript. HK: statistical analyses, critical revision and final approval of the manuscript. MW: methodology design, critical revision and final approval of the manuscript. TWJH: interpretation of the results, critical revision and final approval of the manuscript. HUS: study concept and design, interpretation of the results, critical revision and final approval of the manuscript. RT: study concept and design, interpretation of the results, drafting and revising the manuscript critically, final approval of the manuscript. SR-D: study concept and design, statistical analyses, interpretation of the results, drafting and revising the manuscript critically, final approval of the manuscript. Department of Biobank Research at Umeå University: providing patient samples and data. Västerbotten Intervention Programme: providing patient samples and data. The Northern Sweden MONICA study: providing patient samples and data. The County Council of Västerbotten: providing patient samples and data. J.W. Drijfhout: providing the CCP2 peptides.

  • Funding This work has been financially supported by ReumaNederland (17-1-402), the IMI funded project RTCure (777357), ZonMw TOP (91214031), the Swedish Research Council (VR 2017-00650) as well as the King Gustaf V’s 80-Year Fund, the King Gustaf V’s and Queen Victoria’s Fund and the Swedish Rheumatism Association.

  • Competing interests HUS, TWJH and REMT are mentioned inventors on a patent on ACPA-IgG V-domain glycosylation.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.